Another PI3K-α/δ inhibitor, AZD8835, demonstrated remarkable potency in ABC-like DLBCL models by inhibiting NF-κB signaling and had a synergistic effect with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib both in vitro and in vivo [218] (Table 3). Here, BTK is linked to aneurysmal bone cyst.